BioSpace News Archive

BioArctic AB’s partner Eisai will present the latest findings on lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Novanta Inc., a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2023 results on Tuesday, August 8, 2023.

CVRx, Inc. announced that it plans to release second quarter 2023 financial and operating results after market close on Tuesday, July 25th, 2023.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock.

Travere Therapeutics, Inc. announced that on July 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 13,750 shares of its common stock.

Daré Bioscience, Inc. (NASDAQ: DARE) today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.

Bridge Biotherapeutics announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.

JDRF, the leading global type 1 diabetes research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program and support policies to ensure insulin is available at an affordable and predictable price.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the “Acquisition”).